CNXU - From Accumulation to Momentum Expansion!Conexeu Sciences, Inc.BATS:CNXUTheSignalystAs highlighted in our previous analysis (attached on the chart), CNXU has now officially broken above its accumulation structure and appears to be entering the next phase of the move.⚠️ Following the initial Nasdaq debut volatility and post-IPO correction, bulls managed to reclaim the upper bound of the accumulation range, signaling that momentum may be shifting back in favor of buyers.📈 📊From a technical perspective, this breakout is important because fresh IPOs often transition through clear market structure phases: • Initial price discovery • Post-IPO correction • Accumulation • Markup phase And CNXU now appears to be entering that markup phase. 📈As long as bulls maintain control above the previous accumulation zone, we will be looking for trend-following long opportunities on every correction. Since CNXU is still a newly listed stock with limited historical price data, traditional resistance zones remain relatively undeveloped. Because of that, psychological round numbers become increasingly important during price discovery. 🎯Targets: • First bullish objective: $15 • Second bullish objective: $20 • Beyond that, price discovery remains largely open if momentum expansion continues. 🚀 📰From a fundamental perspective, CNXU continues attracting speculative attention through its regenerative medicine narrative and 3D biofabrication technologies. The company recently introduced its B.R.E.A.S.T.™ bio-regenerative tissue platform, designed to move reconstruction beyond traditional implants and toward biologically supported tissue regeneration. 🧬 In brief, CNXU appears to be transitioning from accumulation into markup, while fresh price discovery conditions continue supporting momentum expansion. ⚠️ Disclaimer: This is not financial advice. Always do your own research and manage risk properly. 📚 Stick to your trading plan regarding entries, risk, and management. Good luck! 🍀 All Strategies Are Good; If Managed Properly! ~Richard Nasr